Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 15, 2020

View Archived Issues

Profiling of JAK inhibitors AZD-4604 and AZD-0449 in translational rodent model of asthma

Oxygen grows tumors but shrinks metastasis chances

GlyT1 inhibitor BI-425809 to improve cognition impairment in schizophrenia

GTEx explores variation in genome bureaucracy

Killing persisters with less toxicity

miR-26a as biomarker of pulmonary exacerbation in cystic fibrosis

OD-66 restores hemoglobin levels in model of cancer-induced anemia

InflaRx initiates phase III of phase II/III study with IFX-1 in severe COVID-19-induced pneumonia

Lmito Therapeutics discloses NQO1 activators

Newave Pharmaceutical divulges BTK inhibitors

Cerepeut describes new quinazolinone compounds

Praxis Biotech presents new ISR pathway inhibitors

Novel IRE1 inhibitors identified by Genentech

Intranasal SARS-CoV-2 vaccine ChAd-SARS-CoV-2-S shows promise in vivo

Phase IIb topline results for Diamyd in type 1 diabetes

89bio reports phase Ib/IIa topline data on BIO89-100 in NASH

Celltrion reports interim phase I data of COVID-19 treatment candidate CT-P59 in healthy subjects

Immunity Pharma reports interim data from phase I/IIa study of IPL-344 in ALS

Cassava reports final phase IIb study results with sumifilam in Alzheimer's disease

CAEL-101 enters phase III program for AL amyloidosis

Gannex files IND for FXR agonist ASC-42 to treat NASH

FDA clears Vaxart's IND for phase I study of oral COVID-19 vaccine candidate

New phase II study evaluates patritumab deruxtecan for advanced/metastatic colorectal cancer

LB reports first-in-human data with amisulpride derivative LB-102

Clinuvel begins DNA repair program with Scenesse

ACTT-2 study of baricitinib plus remdesivir in COVID-19 meets primary endpoint

Cyxone plans to study rabeximod in phase II trial for COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...